Ipilimumab: controversies in its development, utility and autoimmune adverse events.

PubWeight™: 3.62‹?› | Rank: Top 1%

🔗 View Article (PMID 19198837)

Published in Cancer Immunol Immunother on February 06, 2009

Authors

Jeffrey Weber1

Author Affiliations

1: H. Lee Moffitt Cancer Center and Research Institute, Donald A. Adam Comprehensive Melanoma Research Center, Department of Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA. Jeffrey.Weber@moffitt.org

Articles citing this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64

Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28

Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97

Antibodies to watch in 2010. MAbs (2010) 1.90

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90

Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86

Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86

Therapeutic antibodies, vaccines and antibodyomes. MAbs (2010) 1.75

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm (2010) 1.22

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res (2013) 1.11

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One (2010) 1.09

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08

Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05

Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer (2015) 0.92

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes (2012) 0.92

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther (2012) 0.91

Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale J Biol Med (2011) 0.88

What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) (2012) 0.88

Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87

Use of ipilimumab in the treatment of melanoma. Clin Pharmacol (2013) 0.86

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol (2013) 0.86

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer (2014) 0.86

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J (2011) 0.86

Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother (2015) 0.85

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85

Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med (2014) 0.85

Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports. Cancer Invest (2012) 0.84

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol (2016) 0.83

Vaccination in the elderly. Microb Biotechnol (2011) 0.82

Update: immunological strategies for prostate cancer. Curr Urol Rep (2010) 0.82

Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med (2014) 0.82

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol (2017) 0.81

Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol Res Pract (2011) 0.80

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80

Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer (2016) 0.78

Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clin Med Insights Oncol (2012) 0.78

Evolution of multidisciplinary brain metastasis management: case study and literature review. Yale J Biol Med (2015) 0.77

T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron (2013) 0.77

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol (2015) 0.77

18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis. Eur J Nucl Med Mol Imaging (2011) 0.77

Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer (2013) 0.76

Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. Exp Ther Med (2016) 0.75

Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer (2016) 0.75

PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res (2016) 0.75